share_log

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1.5

Benzinga ·  Mar 21 19:08

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Equal-Weight and lowers the price target from $2 to $1.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 336

Recommended

Write a comment